Lectroject Herpes Treatment
Results | Medical Report
Lectroject Particle Transport Unit, as a Carrier of Specific Anti-Virals.
The Lectroject iontophoretic drug delivery device was perfected in 2001 at which time it went to trial. An appeal was published in the news media for volunteers suffering from Herpes, CMV, Coxsackie and HIV. The response was disappointing, with only two HIV/AIDS patients willing to participate.
Herpes sufferers were numerous, but out of fear of some stigma associated with STD’s 90% would not allow their names to be used in any way, not even to colleagues of ours. 300 volunteers took part in this double blind trial.
Volunteers were all between the ages of 25 and 45 years with exception of one person aged 61 years and two teenagers. Male and female were equal in numbers. 90% were either unmarried or divorced. All volunteers were in the upper income bracket.
Currently FDA approved drugs for the treatment of herpes (simplex I and II) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the sites where the herpes virus is replicating. Iontophoresis uses electric current to enhance delivery of drugs through the skin. This trial is testing a new particle transport device Lectroject with acyclovir (Brand name Zovirax) cream.
Group Trial Results:Conditions treated were:
|Herpes 1 (A)||Success Rate 85%|
|Herpes 2 (B)||Success Rate 85%|
|Cytomegalovirus (CMV)||Success Rate 95%|
|Coxsackie Virus B1||Success Rate 95%|
|Coxsackie Virus B2||Success Rate 95%|
|Coxsackie Virus B3||Success Rate 95%|
|Coxsackie Virus B4||Success Rate 95%|
|Coxsackie Virus B5||Success Rate 95%|
|Coxsackie Virus B6||Success Rate 95%|
Subjects undergoing treatment were tested by Independent Laboratories before and after undergoing treatment. In each case, 15 œ hour treatments were given.
Mode of Action
The electronic module creates an ionic stream through the patient. The Lectroject System emits a particle which follows the ionic stream to the + electrode. A small quantity of Acyclovir is placed under the applicator pads. The particle tacks through the Acyclovir, collects an atom of the medication and deposits in the affected cell where it interferes with the viral DNA and so prevents replication, the virus becomes dormant and is eventually eliminated from the body in a normal way. (By catabolism)